Business
Actinium Presents Data Showing ATNM-400 is More Efficacious than Pluvicto and is Highly Efficacious after Pluvicto Resistance in Prostate Cancer Tumor Models at the American Association for Cancer Research Annual Meeting
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced preclinical results with ATNM-400 in prostate cancer models presented at the American Association for Cancer Research (AACR) Annual Meeting. ATNM-400 is a novel, non-PSMA targeting, first in class targeted radiotherapy utilizing the Actinium-225 (Ac-225) radioisotope that Actinium is evaluating in prostate cancer models prior to and following tr
About this update from Actinium Pharmaceuticals, Inc. (delaware)
[{"type":"text","content":"- Results highlight ATNM-400's potential as a transformative therapeutic option for prostate cancer patients with unmet clinical needs as expression of the target receptor for ATNM-400 persists following Pluvicto therapy and ATNM-400 demonstrates sustained tumor control after Pluvicto stops working","length":309,"tagName":"p","attribs":{}},{"type":"text","content":"- ATNM-400 showed greater tumor growth inhibition compared to Pluvicto in prostate cancer models with 99.8% tumor growth inhibition achieved with a single 40 µCi/kg dose of ATNM-400 demonstrating the potential to be offered as an alternative option","length":254,"tagName":"p","attribs":{}},{"type":"text","content":"- ATNM-400 was well tolerated with no apparent toxicities at two different dose levels, with efficient clearance from essential organs","length":140,"tagName":"p","attribs":{}},{"type":"text","content":"NEW YORK, April 28, 2025 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced preclinical results with ATNM-400 in prostate cancer models presented at the American Association for Cancer Research (AACR) Annual Meeting. ATNM-400 is a novel, non-PSMA targeting, first in class targeted radiotherapy utilizing the Actinium-225 (Ac-225) radioisotope that Actinium is evaluating in prostate cancer models prior to and following treatment with Pluvicto. Pluvicto (Lu-177-PSMA-617) is a prostate-specific membrane antigen (PSMA) directed radiotherapy radiolabeled with the beta-particle emitter, Lutetitium-177 (Lu-177) is approved for patients with metastatic castration-resistant prostate cancer. Pluvicto is marketed and sold by Novartis and generated sales of $1.39 billion in 2024.","length":900,"tagName":"p"},{"type":"image","alt":"In vivo studies demonstrated that ATNM-400 is more efficacious than Pluvicto and produced a statistically significant (p < 0.0001) reduction in tumor volume in 22Rv1 prostate cancer models demonstrating its transformative therapeutic potential.","displaySize":"","headline":null,"caption":"In vivo studies demonstrated that ATNM-400 is more efficacious than Pluvicto and produced a statistically significant (p Key Data and Highlights From the ATNM-400 AACR Presentation ","length":59,"tagName":"p"},{"ty...